Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REC604a
- Development stage
- Preclinical
- Lead developer
- Recbio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
REC604a is a novel adjuvanted recombinant quadrivalent human papillomavirus (HPV) vaccine candidate developed by Jiangsu Recbio Technology to prevent infections caused by HPV types 6, 11, 16, and 18, thereby reducing the incidence of cervical cancer and anogenital warts.[1][3][5][7][10] It uses recombinant L1 virus-like particles for the four HPV types formulated with Recbio’s proprietary BFA04 adjuvant (benchmarking GSK’s AS04) to enhance immunogenicity, improve cross-protection, and enable a reduced-dose vaccination regimen compared with existing HPV vaccines.[3][5][7] REC604a has completed preclinical studies and received clinical trial (IND) approval from China’s NMPA, with development focused on prophylactic use against HPV infection and related diseases.[1][2][4][5][6][10]
- Other names
- Novel adjuvanted recombinant quadrivalent HPV vaccineRecombinant HPV quadrivalent vaccine (Types 6/11/16/18)
02
Targets
HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on REC604a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REC604a.